top of page

Pipeline

KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of orally delivered small molecules that demonstrate high blood-brain-barrier penetration, selective kinase inhibition, and enhanced clearance of toxic protein buildup associated with neurodegenerative disease.  Additionally, selective inhibition of kinases related to mast cell-mediated inflammatory conditions has the potential to reduce symptoms for patients suffering from immune conditions. 

Discovery

Ph 1

IND-Enabling

Candidate

Target(s)

Pre-clinical

gradient line.jpg

Alzheimer's disease

KFRX03

c-ABL, c-KIT, FYN

Amyotrophic lateral sclerosis (ALS)

KFRX04

c-KIT, PIKFYVE

Frontotemporal dementia

Parkinson's disease (LRRK2 mutant)

KFRX06

c-KIT (mutants)

Parkinson's disease & dementia (PDD)

Mast cell activation syndrome (MCAS)

Urticaria

KFRX05

c-KIT (mutants), LRRK2

KFRX03

Alzheimer's Disease

Target(s) : c-ABL, c-KIT, FYN

Discovery

Pre-clinical

IND-Enabling

Ph 1

KFRX04

Target(s) : c-KIT, PIKFYVE

KFRX05

Amyotrophic lateral sclerosis (ALS)

Mast Cell Activated Syndrome (MCAS)

Urticaria

Target(s) : c-KIT (mutants), LRRK2

Parkinson's Disease & Dementia (PDD)

KFRX06

Parkinson's disease (LRRK2 mutant)

Target(s) : c-KIT (mutants)

Frontotemporal dementia

bottom of page